Overview

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2023-08-16

Target enrollment:

Participant gender:

Summary

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborator:

Pfizer

Treatments:

Immunoconjugates